Noevir Holdings Co., Ltd.
Noevir Holdings Co., Ltd. (4928.T) Financial Performance & Income Statement Overview
Analyze Noevir Holdings Co., Ltd. (4928.T) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Noevir Holdings Co., Ltd. (4928.T) Income Statement & Financial Overview
View the income breakdown for Noevir Holdings Co., Ltd. 4928.T across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $15.23B | $16.80B | $15.59B | $16.61B |
| Cost of Revenue | $4.96B | $5.45B | $5.26B | $5.47B |
| Gross Profit | $10.27B | $11.35B | $10.33B | $11.14B |
| Gross Profit Ratio | $0.67 | $0.68 | $0.66 | $0.67 |
| R&D Expenses | $0.00 | $0.00 | $1.07B | $0.00 |
| SG&A Expenses | $7.73B | $8.18B | $7.92B | $8.29B |
| Operating Expenses | $7.73B | $8.18B | $7.92B | $8.29B |
| Total Costs & Expenses | $12.70B | $13.63B | $13.18B | $13.76B |
| Interest Income | $21.00M | $15.00M | $18.00M | $13.00M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $211.00M | $204.00M | $274.00M | $272.00M |
| EBITDA | $3.05B | $3.38B | $2.68B | $3.12B |
| EBITDA Ratio | $0.20 | $0.20 | $0.17 | $0.19 |
| Operating Income | $2.54B | $3.17B | $2.41B | $2.85B |
| Operating Income Ratio | $0.17 | $0.19 | $0.15 | $0.17 |
| Other Income/Expenses (Net) | $300.00M | $99.00M | $26.00M | $76.00M |
| Income Before Tax | $2.84B | $3.27B | $2.43B | $2.93B |
| Income Before Tax Ratio | $0.19 | $0.19 | $0.16 | $0.18 |
| Income Tax Expense | $1.13B | $2.23B | -$1.04B | $983.00M |
| Net Income | $1.67B | $974.00M | $3.48B | $1.89B |
| Net Income Ratio | $0.11 | $0.06 | $0.22 | $0.11 |
| EPS | $48.83 | $28.49 | $101.88 | $55.42 |
| Diluted EPS | $48.83 | $28.49 | $101.88 | $55.42 |
| Weighted Avg Shares Outstanding | $34.16M | $34.16M | $34.16M | $34.16M |
| Weighted Avg Shares Outstanding (Diluted) | $34.16M | $34.16M | $34.16M | $34.16M |
Financial performance has remained strong, with revenue growing from $16.61B in Q3 2024 to $15.23B in Q2 2025. Gross profit continued to perform well, with margins at 67% in the latest quarter. Operating income reached $2.54B in Q2 2025, holding a steady 17% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $3.05B. Net income rose to $1.67B, keeping EPS at $48.83. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan